People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

As we learn more about GLP-1 drugs like Wegovy and Zepbound, early research suggests that they may be able to improve COPD ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

GLP-1RA use, but not SGLT2i or pioglitazone use, was associated with a statistically significant lower risk for dementia and cognitive impairment.

Khalid bin Abdulaziz Al-Falih and several officials, along with representatives from Novo Nordisk and Lifera. Semaglutide GLP-1 treatments are the global market-leading therapeutics for weight ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business ... up any revenue loss from semaglutide. Revenue grew 95% y/y to $481.1 million, ahead of Wall ...

With the glucagon-like peptide-1 receptor agonists ... a compounding pharmacy sued by Eli Lilly on 1 April, detailing safety shortcomings. Novo Nordisk is treading familiar ground with its semaglutide ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables ... form of its semaglutide GLP-1 weight loss drug.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it. A company ...

Glucagon-like peptide-1 receptor ... three main ways that GLP-1 RAs help to manage blood sugar: All GLP-1 RAs are injected under the skin, except for one. Oral semaglutide is the first and only ...